Euitaek Jung, PhD

Euitaek Jung, PhD, is a research scientist at Neuramedy, a Seoul-based biotechnology company focused on developing treatments for neurodegenerative diseases. He earned his PhD from Konkuk University in Seoul, Korea, where his research centered on the role of resident cells in the tumor microenvironment and their contribution to tumor progression. His work explored the dynamic and complex interactions between cancer cells and surrounding stromal and immune cells, with a particular focus on how individual cell types within this environment can undergo transformation and differentiation into diverse cellular phenotypes. Since joining Neuramedy, Dr. Jung has been studying the therapeutic potential of NM-101, a TLR2-targeting antagonistic antibody, in various neurodegenerative disease models and investigating the mechanisms underlying its efficacy. He is committed to advancing drug discovery and development in the field of neurodegeneration.